ストックスクリーナーアプリを入手
14.92
2.55%
-0.39
前日終値:
$15.31
開ける：
$15.31
24時間の取引高:
603.19K
Relative Volume:
0.60
時価総額：
$1.07B
収益：
$133.62M
当期純損益:
$-177.37M
株価収益率:
-5.1626
EPS:
-2.89
ネットキャッシュフロー:
$23.50M
1週間 パフォーマンス:
-1.97%
1か月 パフォーマンス:
-6.69%
6か月 パフォーマンス:
+79.76%
1年 パフォーマンス:
-37.28%
1日の値動き範囲:
$14.71
$15.36
1週間の範囲:
$14.71
$15.42
52週間の値動き範囲:
$6.92
$24.66
Xencor Inc Stock (XNCR) Company Profile
XNCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
14.92 | 1.09B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-10-29 | アップグレード | Barclays | Underweight → Overweight |
| 2025-09-17 | 再開されました | Barclays | Underweight |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2024-12-12 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 繰り返されました | BTIG Research | Buy |
| 2024-02-28 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 開始されました | BofA Securities | Buy |
| 2022-12-06 | 開始されました | Cowen | Outperform |
| 2022-10-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-21 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-02-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2020-02-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-01-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-08-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-04-12 | 開始されました | Guggenheim | Buy |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2017-03-02 | 開始されました | Instinet | Neutral |
| 2017-03-02 | 繰り返されました | Wedbush | Outperform |
| 2016-10-04 | 開始されました | Piper Jaffray | Overweight |
| 2015-12-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-05 | 繰り返されました | MLV & Co | Buy |
| 2015-02-12 | 繰り返されました | Oppenheimer | Outperform |
| 2015-01-28 | 繰り返されました | MLV & Co | Buy |
| 2014-07-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Xencor Inc (XNCR) 最新ニュース
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Will Xencor Inc. (XE9) stock remain on Wall Street radar2025 Biggest Moves & Entry Point Strategy Guides - Улправда
Why Xencor Inc. stock attracts global investors2025 Institutional Moves & Low Risk High Reward Ideas - Улправда
VP Desjarlais Files To Sell 73,367 Of Xencor Inc [XNCR] - TradingView — Track All Markets
Can Xencor Inc. stock sustain revenue growth2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Will Xencor Inc. stock benefit from upcoming earnings reportsJuly 2025 Big Picture & Advanced Technical Analysis Signals - DonanımHaber
How Xencor Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Low Drawdown Trading Techniques - DonanımHaber
Growth Report: Is Xencor Inc. stock ready for breakoutPortfolio Return Report & Free Safe Entry Trade Signal Reports - Улправда
Can Xencor Inc. stock resist market sell offsJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
How supply shortages influence Xencor Inc. (XE9) stockTrade Entry Summary & Free Community Supported Trade Ideas - Улправда
Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - The Globe and Mail
Barclays Maintains Xencor (XNCR) Overweight Recommendation - Nasdaq
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases - TipRanks
Xencor Earnings Notes - Trefis
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Free cash flow per share of Xencor, Inc. – GETTEX:XE9 - TradingView — Track All Markets
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Pullback Watch: What momentum indicators show for Xencor Inc stock2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Is Xencor Stock Built to Withstand a Pullback? - Trefis
How Xencor Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat
What hedge fund moves indicate for Xencor Inc. (XE9) stockWeekly Earnings Recap & Low Drawdown Investment Strategies - Newser
What momentum indicators show for Xencor Inc. stock2025 Price Action Summary & High Conviction Investment Ideas - Newser
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC) - The Globe and Mail
Its Stock Has Paid Off Big Time For Xencor Inc - setenews.com
Is Xencor Inc. stock a defensive play in 2025Quarterly Profit Review & Daily Growth Stock Investment Tips - Newser
Xencor (XNCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xencor Inc. diskutieren - sharewise.com
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XNCR) 財務データ
収益
当期純利益
現金流量
EPS
Xencor Inc (XNCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 22 '25 |
Option Exercise |
12.51 |
6,311 |
78,951 |
242,885 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 19 '25 |
Sale |
15.72 |
73,367 |
1,153,329 |
236,574 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Option Exercise |
12.51 |
114,377 |
1,430,856 |
581,012 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 22 '25 |
Option Exercise |
12.51 |
10,624 |
132,906 |
477,259 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Sale |
15.71 |
114,377 |
1,796,863 |
466,635 |
0.57%
大文字化:
|
ボリューム (24 時間):